Due to the highly biosynthetic nature of LLPC/myeloma, drugs that target protein degradation through proteasome inhibition have been highly effective in MM treatment even though it was initially thought that the mechanism by which proteasome inhibitors killed MM was through the inhibition of the transcription factor NF-κB [88]. This evidence concerns the gene NFKB1 and plasma cell myeloma.